Shedir Pharma Group Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Antonio Scala
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Shedir Pharma Group S.p.A.'s (BIT:SHE) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Nov 08
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 05Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem
Oct 05Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?
Apr 06What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 30
CEO
Antonio Scala (40 yo)
6yrs
Tenure
Mr. Antonio Scala serves as Managing Director and Chief Executive Officer of Shedir Pharma Group S.P.A. since 2019 and serves as its Director. Mr. Scala graduated in International Economics at the Universi...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | no data | no data | no data | |
| Director | no data | no data | no data | |
| Chairman of the Board | 9yrs | no data | 88.01% € 49.0m | |
| Director | 6yrs | no data | no data | |
| Independent Director | 6yrs | no data | no data | |
| Statutory Auditor | 5.5yrs | no data | no data | |
| Statutory Auditor | 6.1yrs | no data | no data | |
| President of the Board of Statutory Auditors | no data | no data | no data |
6.0yrs
Average Tenure
51yo
Average Age
Experienced Board: SHE's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 03:59 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shedir Pharma Group S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gian Gadini | Banca Akros S.p.A. (ESN) |
| Maria Di Grado | KT & Partners Srl |